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tenolol Is Dead:
ong Live Beta-Blockade
angalore et al. (1) recently reported that a lower heart rate was
ssociated with a greater risk for all-cause mortality (r  0.51;
 0.0001), cardiovascular mortality (r  0.61; p  0.0001),
yocardial infarction (MI) (r  0.85; p  0.0001), stroke
r  0.20; p  0.06), or heart failure (r  0.64; p  0.0001).
hey concluded that beta-blocker–associated reduction in heart
ate increased the risk of cardiovascular events and death in
ypertensive patients, in contrast to patients with MI and heart
ailure. In an accompanying editorial, Kaplan (2) stated that
eta-blockers will continue to be indicated for heart failure,
achyarrhythmias, and secondary prevention post-MI, but not
or treatment of hypertension in patients without these com-
elling indications. However, as the authors wrote, care should
e taken in extrapolating these findings to newer beta-blockers,
specially the vasodilating agents (e.g., nebivolol and carvedilol)
3). It should be emphasized that the studies included in this
eview used atenolol almost exclusively: 78% of patients received
tenolol; 12%, atenolol/metoprolol/pindolol or hydrochlorothi-
zide; 9%, oxprenolol; and 1%, propranolol. Thus, it is difficult
o extrapolate the findings to newer vasodilating beta-blockers.
uture studies should strive to determine whether atenolol per
e or the reduction of heart rate is responsible for increased
ardiovascular risk. This issue needs to be resolved, because the
ndings would have major clinical implications (3).
Another important issue to resolve is the effect of drugs on
entral pressure. The benefits of heart rate reduction may be
egated by a drug that lowers heart rate while simultaneously
ncreasing central pressure (4). Different drugs, especially beta-
lockers, have differential effects on peripheral and central pres-
ure, and a number of studies have now shown that central pressure
s a better predictor of outcome than pressure in the arm (5,6). As
emonstrated in the CAFE (Conduit Artery Function Evaluation)
tudy, antihypertensive medications can have substantially different
ffects on central aortic pressure and hemodynamics, despite a
imilar impact on brachial blood pressure (7). Vasodilatory beta-
lockers may well offset any deleterious hemodynamic effects of
eart rate reduction by decreasing wave reflection from the
eriphery. In a study by Dhakam et al. (8), the central hemody-
amic effects of nebivolol and atenolol were compared in patients
ith systolic hypertension. Despite similar reductions in peripheral
lood pressure, nebivolol reduced central pulse pressure more than
tenolol. Both drugs reduced aortic stiffness, but nebivolol had less
mpact on the aortic augmentation index. These findings suggest hhat important differences may exist among drugs in the beta-
locker class.
Finally, beta-blockade remains very important in the treatment
f cardiovascular disease, and in hypertensive patients with coex-
sting angina. Further, hypertensive patients younger than 50 years
ld may benefit more from beta-blockade than older patients, as
hey have a different hemodynamic form of hypertension (9).
owever, all evidence to date (4) suggests that a beta-blocker other
han atenolol should be chosen when beta-blockade is required.
It is premature to sound the death knell for all beta-blockers in
he treatment of hypertension based upon the Bangalore et al. (1)
eview, but it is high time to stop prescribing atenolol.
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eta-Blockers, Hypertension, and
andomized Controlled Trials:
cience and Sensibility
angalore et al. (1) suggest that beta-blocker–induced reduction of
eart rate increases the risk for cardiovascular events and death for
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June 2, 2009:2101–7ypertensive patients. Results of meta-analyses should be viewed
ith circumspection, especially when clinical practice might be
nfluenced (2). With one-fifth of the general population suscepti-
le to migraine (and other primary vascular headaches) and with
onvasodilating beta-blockers still regarded as first-line preventive
gents, the conclusions of this study (1) raise concern. The authors
dmittedly ignore the dose of atenolol (1), a critical variable that
imits this analysis. Besides, biologically, in no 2 patients can the
volution of atherosclerosis or its complications be strictly compa-
able. Statistics do permit such mathematical comparisons in
andomized controlled trials (RCTs), but they can extract a hidden
iological price (3).
First, contrary to the assertion that the “slower the heart rate,
he greater the benefit” (1), heart rates below 50 beats/min cannot
enerally be claimed to promote overall cardiovascular integrity.
econd, the negative inotropic action of beta-blockers has been
gnored in this study (1) as well as in the CAFE (Conduit Artery
unctional End Point) study (4). Any rise in central aortic
ressure/pulse pressure by nonvasodilating beta-blockers would be
ntrinsically countered by their negative inotropic action. A phar-
acologically reduced stroke volume would maximally affect cen-
ral conduit vessels to reduce central vessel wall stress. Not
urprisingly, atenolol reduces the elevated augmentation index in
ypertensive patients compared with that in normotensive subjects
5). Third, the investigators (1) did not stratify their results
ccording to age. An aging cohort is likely to have stiffer conduit
rteries that, in turn, would exacerbate any differential drug effects
n central aortic pressure (4). Fourth, the concept of dyssynchrony
r uncoupling between outgoing and reflected aortic waves conse-
uent to pharmacologically induced bradycardia (1) is purely
peculative.
Cardiovascular morbidity and mortality are too complex to be
esolved through multiple mathematics-based comparisons of
iverse pharmacologic agents, particularly when polytherapy with
everal drugs might be involved. Moreover, all vasodilators usually
orsen migraine headache; among antihypertensive agents, beta-
lockers, however, do not generally aggravate headache. Regardless
f age or race, hypertension is commonly associated with headache
hat has several features of migraine (6). Proscription of beta-
lockers for initial or primary management of hypertension will
ncrease the incidence of associated vascular headaches including
igraine and make their management more complex. Next,
eta-blockers hold center stage in management of predominantly
ystolic hypertension as well as the anxiety-related white coat
ypertension/effect. Weight gain and precipitation of diabetes
ellitus by beta-blockers is a relative risk unrelated to pancreatic
slet cell damage.
In essence, this study (1) and the accompanying editorial (7)
eek to convert a small-to-moderate statistical relative risk into an
bsolute biological risk with important practical implications.
CTs allow scientists to carry out credible research without having
o discern crucial clinical phenomena or diminishing the need for
he same (3). While using research tools such as RCTs or
eta-analysis involving RCTs, we must remain cognizant of the
ntrinsic biological limitations of mathematical data mining. To
eek or force a clinical/therapeutic consensus in the face of
iological uncertainty cannot be commended as the best scientific/
esearch practice. wVinod Kumar Gupta, MB, BS, MD
Gupta Medical Centre
ew Delhi 110 048
ndia
-mail: dr_vkgupta@yahoo.com
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eta-Blocker–Induced
eart Rate Reduction
oo Simplistic to Explain the
eleterious Effects of Beta-Blockers
n their recently published article, Bangalore et al. (1) con-
luded, from a meta-regression analysis of 9 studies including a
otal of 34,096 patients taking beta-blockers as first-line therapy
nd 30,139 patients taking other antihypertensive agents, that
eta-blocker–associated reduction in heart rate increased the
isk of myocardial infarction, cardiovascular events, and death
or hypertensive patients. The authors suggested, as a mecha-
ism, that “pharmacologically induced bradycardia leads to
yssynchrony or uncoupling between outgoing and reflected
ave, thereby elevating central aortic pressure.” They referred
o the CAFE (Conduit Artery Functional End Point) study,
hich showed a higher central aortic systolic blood pressure
fter atenolol-based treatment than after amlodipine-based
reatment, and to the main ASCOT (Anglo-Scandinavian
ardiac Outcomes Trial) study showing a better predictive
alue for cardiovascular events of amlodipine-based treatment
han atenolol-based treatment. Although appealing, their con-
lusion that beta-blockers are deleterious through the reduction
n heart rate, thus increasing central pulse pressure, may be too
implistic and not supported by data.
Indeed, although the authors pointed out that resting heart rate
as an independent risk factor for cardiovascular morbidity and
